巴楚医学2025，Vol.8Issue(1)：109-113,5.DOI:10.3969/j.issn.2096-6113.2025.01.019
布地奈德福莫特罗联合噻托溴铵治疗稳定期哮喘合并COPD患者的临床疗效分析
Clinical Effect of Budesonide-Formoterol Combined with Tiotropium Bromide in the Treatment of Patients with Stable Asthma and COPD
摘要
Abstract
Objective:To evaluate the clinical effect of combined treatment with budesonide-formoterol and tiotropium bromide in patients with stable asthma and chronic obstructive pulmonary disease(COPD).Methods:A total of 91 patients with stable asthma and COPD admitted to Nanjing Lishui District People's Hospital from April 2020 to January 2022 were selected and divided into two groups based on whether tiotropium bromide powder was added to their treatment.The control group(n=50)used budesonide-formoterol powder inhaler,while the observation group(n=41)used tiotropium bromide powder inhaler in addition to budesonide-formoterol powder inhaler.The asthma control test scores,COPD assessment test(CAT)scores,lung function FEV1-FEV1 predicted value(％),EuroQol five-dimension five-level(EQ-5D)quality of life scale,and adverse reactions were compared between the two groups after 12 months of treatment.Results:After 12 months of treatment,the CAT score of the observation group[(12.85±1.82)vs(14.05±1.52)]was significantly lower than that of the control group(P＜0.05);the FEV1/FEV1 predicted value[(65.64±4.64)％vs(63.23±5.42)％],EQ-5D score[(0.90±0.03)vs(0.87±0.03)],EQ-VAS score[(82.63±7.10)vs(78.60±8.76)],and treatment efficiency(87.80％vs 70.00％)were all significantly higher than those of the control group(all P＜0.05).Conclusion:The combined treatment of budesonide-formoterol and tiotropium bromide can effectively improve the clinical efficacy and lung function in patients with stable asthma and COPD,thereby enhancing the quality of life of patients,which is worthy of further clinical promotion and application.关键词
哮喘/慢性阻塞性肺疾病/布地奈德福莫特罗/噻托溴铵Key words
asthma/chronic obstructive pulmonary disease(COPD)/budesonide-formoterol/tiotropium bromide分类
医药卫生引用本文复制引用
黄雅菲,高振云,刘佳,房树华..布地奈德福莫特罗联合噻托溴铵治疗稳定期哮喘合并COPD患者的临床疗效分析[J].巴楚医学,2025,8(1):109-113,5.基金项目
江苏省药学会—天晴医院药学基金项目(Q202054) （Q202054）
